REVUE DE PRESSE
Réf. :HematoStat.net ; 2 (10) : R54 Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer […]
Réf. :HematoStat.net ; 2 (7) : R53 Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Al-Sawaf O, Zhang C, Lu T, Liao […]
Réf. :HematoStat.net ; 2 (7) : R52 Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized […]
Réf. :HematoStat.net ; 2 (6) : R51 Lagerlöf I, Fohlin H, Enblad G, Glimelius B, Goldkuhl C, Palma M, et al. Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage […]